GPT and Cirrhosis: In the adjusted Cox regression analysis, after adjustment for age, ALT, AST, hemoglobin, platelet, lymphocytes, neutrophils, tumor size, gender, HBV infection, AFP level, TACE session, tumor number, cirrhosis, and ECOG, TACE-A did not increase the mortality risk (Child-Pugh A: HR: 0.590, 95%CI: 0.305–1.140, P=0.116; Child-Pugh B: HR: 1.056, 95%CI: 0.612–1.824, P=0.844) or tumor recurrence risk (Child-Pugh A: HR: 0.631, 95%CI: 0.349–1.140, P=0.127; Child-Pugh B: HR: 1.066, 95%CI: 0.648–1.754, P=0.802) compared to TACE-S in the patients with Child-Pugh A and B scores.